Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.
Zacks Investment Research on MSN2d
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $420.00 Price Target at Royal Bank of Canada
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...
Lutnick Family’s BGC Group Buys Brokerage OTC for $325 Million
BGC Group Inc., a financial firm controlled by the billionaire Lutnick family, bought brokerage OTC Global Holdings for $325 ...